Eliem Therapeutics

United States
Melba, Idaho, United States, 98053

Company profile

Eliem Therapeutics company profile

Eliem Therapeutics is a clinical-stage biotechnology company developing treatments for nervous system disorders. The company leverages its expertise in neuroscience, translational medicine, and clinical development to meet this unmet medical need with a highly innovative pipeline. Eliem Therapeutics develops and commercializes potentially “best-in-class” drug candidates to treat neuronal excitability disorders. These conditions—such as chronic pain, depression, epilepsy, and anxiety—cause deep suffering for tens of millions of people each day. At its core, the Eliem team is motivated by the promise of helping patients live happier, more fulfilling lives.

Business identity

Contact email
[email protected]
Operating status
Active
Company type
For Profit
Employee range
11-50 employees
Revenue range
$0-$1M
Founded
2018-01-01, Year

Headquarters

Postal code
98053
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding stage
IPO
Funding rounds
6
Total equity funding
$291.3M
Last funding
Post IPO Equity / $120M / 2024-04-11
Last equity funding
Post IPO Equity / $120M
Investors
11
Lead investors
3
Founders
3
Articles
87
Exited on
2021-08-10

Founders and investors

Founders

Andrew LevinDavid-Alexandre GrosValerie Morisset

Lead investors

Access BiotechnologyIntermediate Capital GroupRA Capital Management

Investors

Intermediate Capital GroupJanus Henderson InvestorsLifeArcRA Capital ManagementSamsara BioCapital